Cellular Dynamics International, Inc. announced an exclusive agreement with SeouLin Bioscience Co. Ltd., for the distribution of CDI's products in the Republic of Korea. Under the terms of the agreement, SeouLin Bioscience will distribute CDI's iCell® catalog of products.

CDI's iCell products are human induced pluripotent stem cell (iPSC)-derived tissue cells, including cardiomyocytes, hepatocytes, and neurons, among others totaling up to 12 cell types, as well as special media if required. Under discussion is the expansion to distribute the MyCell® catalog of products. CDI's MyCell Products enable researchers to better understand the phenotypic underpinnings of a disease of interest, as they submit donor samples to CDI for the manufacture of iPSCs and tissue cells from them.

In addition, MyCell Products are already available for diseases such as cardiac arrhythmias, Alzheimer's and Parkinson's diseases, drug-induced liver injury, and muscular dystrophies. As part of the agreement, SeouLin Bioscience will handle first-level technical support inquiries from its customers.